|
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL. |
|
|
Consulting or Advisory Role - CTI; Genentech |
Research Funding - Bristol-Myers Squibb; Celgene; CTI; Gilead Sciences |
|
|
Stock and Other Ownership Interests - Kite, a Gilead company |
Consulting or Advisory Role - Bayer; Celgene; Gilead Sciences |
Speakers' Bureau - Bayer; Celgene; Gilead Sciences; Pharmacyclics |
Research Funding - Bayer; Celgene; Gilead Sciences; Incyte; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Celgene; Takeda |
|
|
Honoraria - TG Therapeutics |
Consulting or Advisory Role - Gilead Sciences; Seagen |
Research Funding - Acerta Pharma (Inst); Amgen (Inst); Celgene (Inst); Cell Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Novartis (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - TG Therapeutics |
|
|
Consulting or Advisory Role - Celgene; Spectrum Pharmaceuticals |
Research Funding - Spectrum Pharmaceuticals (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Employment - Bristol-Myers Squibb (I); Celgene |
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Celgene |
Patents, Royalties, Other Intellectual Property - Momenta Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; TG Therapeutics |
Speakers' Bureau - Gilead Sciences |
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst) |
Expert Testimony - Gilead Sciences |